ImmunityBio Grapples with Legal Fallout and Clinical Progress

ImmunityBio hit with class actions after FDA warning letter on Anktiva claims triggers a 21% stock drop. Company responds with corrective steps as clinical trials and revenue growth continue.

A wave of shareholder lawsuits is crashing over ImmunityBio following a regulatory rebuke from the U.S. Food and Drug Administration (FDA). The legal actions, consolidated under Douglas v. ImmunityBio, Inc. in the U.S. District Court for the Central District of California, allege the company and certain executives made misleading statements about its cancer drug Anktiva. The core allegation is that material information was withheld from investors between January 19 and March 24, 2026.

The controversy stems from a podcast featuring Executive Chairman Dr. Patrick Soon-Shiong on January 19, 2026, titled "Is the FDA Blocking Lifesaving Cancer Treatments?" In it, Soon-Shiong suggested Anktiva could cure or even prevent all cancers. The FDA deemed these claims, along with those in a prepared TV advertisement, "false or misleading." A formal warning letter was sent to CEO Richard Adcock in mid-March and made public on March 24, 2026.

Market reaction was swift and severe. Upon the letter's release, ImmunityBio's stock price plummeted more than 21% on extremely high volume, closing at $7.42. The single-day collapse wiped out nearly $2 billion in market capitalization. This event triggered the legal onslaught, with firms including Kaplan Fox & Kilsheimer, Faruqi & Faruqi, Hagens Berman, and Kessler Topaz Meltzer & Check filing or joining class actions by April 8. Investors have until May 26, 2026, to apply as lead plaintiff in the formal proceedings.

In response to the FDA, ImmunityBio has taken several corrective steps. On April 6, 2026, the company submitted a comprehensive formal response to the FDA's Office of Prescription Drug Promotion. The contentious podcast was removed from its website, and third-party platforms were asked to delete it. ImmunityBio also confirmed the implicated TV ad never aired and announced enhanced internal controls and external regulatory oversight.

Financially, the company shows significant operational growth despite the legal overhang. Full-year 2025 revenue surged over 668% to $113.3 million, while the net loss narrowed by approximately 15% to $351.4 million. ImmunityBio recently secured an additional $75 million in non-dilutive financing from Oberland Capital, bringing the total facility to $375 million. In a separate move signaling confidence, a major investor converted $25 million in debt into 4.6 million shares of common stock.

Operationally, the clinical program for Anktiva continues apace. The randomized QUILT-2.005 study, fully enrolled with 366 patients, is progressing. An independent data monitoring committee confirmed the trial has sufficient power to measure its primary endpoint. Recent interim results showed a markedly improved response rate for the combination of Anktiva and BCG versus standard therapy alone. The company also recently gained regulatory approval for Anktiva in Macau, marking its first market entry in Asia and supporting a global expansion strategy targeting over 30 countries.

Looking ahead, ImmunityBio plans to submit a supplemental Biologics License Application (BLA) in the United States in the fourth quarter of 2026. Analyst sentiment remains fundamentally positive, with an average rating of "Strong Buy." The immediate future, however, is defined by a confluence of active litigation, an ongoing FDA compliance process, and the anticipation of critical clinical data expected later this year.